Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas

Surgical Neurology

Volumn 70, Issue 3, 2008, Pages 259-266

  da Fonseca, Clovis Orlando ^a   Schwartsmann, Gilberto ^b   Fischer, Juliana ^c   Nagel, Janaína ^d   Futuro, Débora ^e   Quirico Santos, Thereza ^e   Gattass, Cerli Rocha ^c  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d Department of Oral and Maxillofacial Surgery   (Brazil)

^e FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Adjuvant chemotherapy; Gliomas; Perillyl alcohol; Phase I II clinical trials

Indexed keywords

PERILLYL ALCOHOL; TEMOZOLOMIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MONOTERPENES; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEIN P21(RAS); SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 48549098794     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surneu.2007.07.040     Document Type: Article

References (23)

1. Ariazi E.A., Satomi Y., Elis M.J., Haag J.D., Shi W., Satler C.A., and Gould M.N. Activation of the transforming growth factor beta signaling pathway and induction of cytotasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59 (1999) 1917-1928
2. Azzoli C.G., Miller V.A., Ng K.K., Krug L.M., Spriggs D.R., Tong W.P., Riedel E.R., and Kris M.G.A. Phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 51 (2003) 493-498
3. Bailey H.H., Levy D., Harris L.S., Schink J.C., Foss F., and Wadler A.S. Phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer. Eastern Cooperative Oncol 3 (2002) 464-468
4. Barakat N.S., Omar S.A., and Ahmed A.A. Carbamazepine uptake into rat brain following intra-olfactory transport. J Pharm Pharmacol 58 (2006) 63-72
5. Belanger J.T. Perillyl alcohol: applications in oncology. Altern Med Rev 3 (1998) 448-457
6. Bhaskara V.K., Panigrahi M., Challa S., and Babu P.P. Comparative status of activated ERK1/2 and PARP cleavage in human gliomas. Neuropathology 25 (2005) 48-53
7. Da Fonseca CO, Landeiro JA, Clark SS, Quirico-Santos T, da Costa Carvalho Mda G, Gattass CR. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg Neurol 2006;65 Suppl 1:S1:2-1:8.
8. Da Fonseca C.O. Effects of in vitro and in vivo treatment of monoterpene perillyl alcohol on proliferation and gene expression control of high grade gliomas. Arq Neuro-Psiquiatr 62 (2004) 1117-1118
9. Fernandes J., Da Fonseca C.O., Teixeira A., and Gattass C.R. Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells. Oncol Rep 13 (2005) 943-947
10. Fischer J.S.G., Silva M.M.S., Carvalho P.C., Paschoal M.P., Gattass C.R., and Carvalho M.G.C. Effect of perillyl alcohol on gene expression of human pulmonary adenocarcinoma cells. Jornal Brasileiro de Pneumologia 31 (2005) 373-381
11. Holstein S.A., and Hohl R.J. Monoterpene regulation of Ras and Ras-related protein expression. J Lipid Res 44 (2003) 1209-1215
12. Mandell J.W., Hussaini I.M., Zecevic M., Webert M.J., and VandenBerg S.R. Immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. In situ visualization of intratumor growth factor signaling. Am J Pathol 153 (1998) 1411-1423
13. Jeffers L. The effect of perillyl alcohol on the proliferation of human prostatic cell lines. Proc Am Assoc Cancer Res 36 (1995) 303
14. Mills J.J., Chari S.S., Boyer I.J., Gould M.N., and Jirtle R.L. Induction apoptosis in liver tumors by the monoterpe perillyl alcohol. Cancer Res 55 (1995) 979-983
15. Mischel P.S., and Cloughesy T.F. Targeted molecular therapy of GBM. Brain Pathol 13 (2003) 52-61
16. Ni Chonghaile T., Concannon C.G., Szegezdi E., Gorman A.M., and Samali A. Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-X(L). Apoptosis (2006) [electronic publication ahead of print]
17. Rajesh D., Stenzel R.A., and Howard S.P. Perillyl alcohol as a radio-/chemosensitizer in malignant glioma. J Biol Chem 19 (2003) 35968-35978
18. Reddy B.S., Wang C.X., Samaha H., et al. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 57 (1997) 420-425
19. Shi W., and Gould M.N. Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 23 (2002) 131-142
20. Stayrook K.R., McKinzie J.H., Burke Y.D., Burke Y.A., and Crowell P.L. Induction of the apoptosis-promoting Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 18 (1997) 1655-1658
21. Stupp R., and Weber D.C. The role of radio and chemotherapy in glioblastoma. Onkologie 28 (2005) 315-317
22. Teruszkin I., Alves S., Silva H.N., Curie C.M., Bozza M., Fonseca C.O., and Da Costa C.M.G. Effects of perillyl alcohol in glial cell line in vitro and anti-metastatic activity in chorioallantoic membrane model. Int J Mol Med 10 (2002) 785-788
23. Yung W.K., Albright R.E., Olson J., Fredericks R., Fink K., Prados M.D., Brada M., Spence A., Hohl R.J., Shapiro W., Glantz M., Greenberg H., Selker R.G., Vick N.A., Rampling R., Friedman H., Phillips P., Bruner J., Yue N., Osoba D., Zaknoen S., and Levin V.A. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593